October Updates to OPPS and ASC PS Announced
Quarterly updates to the Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment System (ASC PS) for separately paid drugs and biologicals, covered surgical procedures, and ancillary services have been released to Medicare contractors. The updates include one newly created pass-through device HCPCS Level II code, five newly created drug HCPCS Level II codes, and six newly created HCPCS Level II codes for imaging services.
October 2010 OPPS Pricer and ASC DRUG file
The following five new HCPCS Level II codes have been created for drugs that are payable as covered ancillary services under the OPPS and ASC PS for service dates on or after Oct. 1.
|HCPCS Code||Long Descriptor||PI||APC||SI|
|C9269||Injection, C-1 esterase inhibitor (human), Berinert, 10 units||K2||9269||G|
|C9270||Injection, immune globulin (Gammaplex), intravenous, non-lyophilized (e.g. liquid), 500 mg||K2||9270||G|
|C9271||Injection, velaglucerase alfa, 100 units||K2||9271||G|
|C9272||Injection, denosumab, 1 mg||K2||9272||G|
|C9273||Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF in 250 mL of Lactated Ringer’s, including leukapheresis and all other preparatory procedures, per infusion||K2||9273||G|
We recently reported on the national coverage analysis (NCA) for Provenge. Until a national coverage determination (NCD) is made by the Centers for Medicare & Medicaid Services (CMS), local contractors will issue local coverage determinations (LCDs) for Provenge based on the medical necessity of the service(s) being provided.
Note: The long descriptor of Provenge stating “all other preparatory procedures” refers to the transportation process of collecting immune cells from a patient during a non-therapeutic leukapheresis procedure, subsequently sending the immune cells to the manufacturing facility, and then transporting the immune cells back to the site of service to be administered to the patient.
Payment Rate Updates
CMS has identified incorrect payment rates for one CPT® code in the April 2010 OPPS Pricer and ASC Drug file and two HPCPS Level II codes in the July 2010 OPPS Pricer and ASC Drug file.
The correct payment rate for CPT® code 90476 Adenovirus vaccine, type 4, live, for oral use is $72.17 and the corrected minimum unadjusted copayment is $14.43, effective for services furnished April 1 – June 30.
Effective for services furnished July 1 – Sept. 30, the correct payment rates for HCPCS Level II codes J9264 Injection, paclitaxel protein-bound particles, 1 mg and C9268 Capsaicin, patch, 10 cm2 in the revised July 2010 OPPS Pricer and ASC Drug file are $9.22 and $25.55, respectively. The corrected minimum unadjusted copayments are $1.84 and $5.01, respectively.
Suppliers who think they may have received incorrect payment for 90476 claims processed between April 1 and June 30 or J9264 and C9268 claims processed between July 1 and Sept. 30 may request an adjustment.
Payment Indicator Updates
The payment indicators for two CPT® codes also have been corrected since first being issued. These changes may affect reimbursement rates. Staff should check claims for the following services furnished between the dates indicated to determine if claims adjustments are warranted.
CPT® code 90670 Pneumococcal conjugate vaccine, 13 valent, for intramuscular use was erroneously assigned status indicator K Paid under OPPS; separate APC payment in the July 2010 OPPS update and ASC payment indicator K2 Drugs and biologicals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate in the July 2010 ASC update.
Effective April 1, the OPPS status indicator for 90670 is changed from K to L Not paid under OPPS. Paid at reasonable cost; not subject to deductible or coinsurance and ASC payment indicator for 90670 is changed from K2 to L1 Influenza vaccine; pneumococcal vaccine. Packaged item/service; no separate payment made. Beginning April 1, 90670 will be paid at reasonable cost and does not appear in the revised April 2010 and revised July 2010 ASC Drug files.
Also changed is the OPPS status indicator for CPT® code 90662 Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use from E to L, and the ASC PI for 90662 from Y5 to L1, effective Dec. 23, 2009, when 90662 received Food and Drug Administration (FDA) approval.
New Pass-Through Device Code
The Outpatient Prospective Payment System (OPPS) adds a new pass-through device code for separate payment, effective Oct. 1.
HCPCS Level II code C1749 Endoscope, retrograde imaging/illumination colonoscope device (implantable) is assigned is assigned OPPS status indicator H Separate cost-based pass-through payment; not subject to coninsurance and ASC payment indicator J7 OPPS pass-through device paid separately when provided integral to a surgical procedure on ASC list; payment contractor-priced.
MRA Coding/Payment Changes
Effective for claims with dates of service on or after June 3, hospitals and ASCs have six new HCPCS Level II codes for billing certain magnetic resonance angiography (MRA) services for which there is no national coverage determination (NCD). Coverage for the following new codes is up to the discretion of your Medicare contractor and its local coverage determinations (LCD).
C8931 Magnetic resonance angiography with contrast, spinal canal
C8932 Magnetic resonance angiography without contrast, spinal canal and contents
C8933 Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents
C8934 Magnetic resonance angiography with contrast, upper extremity
C8935 Magnetic resonance angiography without contrast, upper extremity
C8936 Magnetic resonance angiography without contrast followed by with contrast, upper extremity
These codes are assigned ASC payment indicator Z2 Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS relative payment weight in the MPFS update, effective June 1 – Nov. 30, as authorized by the Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010.
Note that, for Medicare claims, HCPCS Level II codes C8931, C8932, and C8933 replace CPT® code 72159 Magnetic resonance angiography, spinal canal and contents, with or without contrast material(s), and HCPCS Level II codes C8934, C8935, and C8936 replace CPT® code 73225 Magnetic resonance angiography, upper extremity, with or without contrast material(s).
CMS has changed the assignment of codes 72159 and 73255 from status indicator E to B to indicate that these codes are not recognized by OPPS when submitted on an outpatient hospital Part B bill type 12x or 13x. Under the OPPS, the six new HCPCS Level II codes are assigned status indicator Q3 to indicate that these services will be paid with one composite APC payment each time a hospital bills for second and subsequent imaging procedures in the same imaging family on a single service date.
Update: Transmittal 2050, dated September 17, 2010 is rescinded and replaced by Transmittal 2061, dated October 1, 2010. A reference to a special payment indicator (Policy Section 6.B) that incorrectly stated a ‘Y’ has been corrected in the Recurring Update Notification to specify a ‘2’ instead. All other information remains the same.
Latest posts by admin aapc (see all)
- Message From Your Region 6 Representatives | Pam Tienter and Jean Pryor - January 16, 2020
- Message From Your Region 3 Representatives | Astara Crews and Dianne Estes - January 16, 2020
- Message From Your Region 7 Representatives | Robert Kiesecker and Pam Brooks - January 16, 2020